The acquisition will strengthen Sorin’s existing cannulae product line as well as complement the recent acquisition of the Estech’s minimally invasive cannulae product line.
CalMed’s products are approved by the US Food and Drug Administration and European Union, and are available in more than 45 countries worldwide.
Sorin Group cardiopulmonary business unit and intercontinental president Michel Darnaud said, "This deal confirms Sorin Group’s commitment to further strengthen our presence in the cannulae segment and consolidate our relationship with cardiac surgeons and clinical perfusionists worldwide."
CalMed said president and CEO Mehmet Bicakci, "We believe that building on CalMed’s rich product offering and pipeline and leveraging on Sorin’s global sales network will drive to a significant adoption of these products by cardiac surgeons worldwide."
